Case Study: Pharmaxis achieves more efficient mannitol delivery with PA Consulting's Orbital inhaler

The Orbital® inhaler, developed by PA for Pharmaxis, is being used in key research to combat tuberculosis

Pharmaxis, working with PA Consulting, needed to make daily inhaled mannitol treatment easier for people with cystic fibrosis. The existing regimen required patients to use ten separate 40mg capsules twice a day, creating a heavy treatment burden and adding to the time spent managing their condition.

PA Consulting designed and developed the Orbital inhaler to deliver a full 400mg dose of mannitol with far fewer inhalations and no need to load or reload capsules. The device was independently shown to deliver mannitol and other drugs more efficiently than existing inhalers, reducing the dose to just five to six inhalations and opening up potential use in cystic fibrosis and tuberculosis research.

Pharmaxis